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Abstract
Background—Allelic variations in TPH2, the gene encoding tryptophan hydroxylase 2, the rate-
limiting enzyme for brain serotonin (5-HT) biosynthesis, may be genetic predictors of panic 
disorder and panic responses to panicogenic challenges in healthy volunteers. To test the 
hypothesis that tph2 mRNA is altered in chronic anxiety states, we measured tph2 expression in an 
established rat model of panic disorder.
Methods—We implanted 16 adult, male rats with bilateral guide cannulae and then primed them 
with daily injections of the corticotropin-releasing factor (CRF) receptor agonist, urocortin 1 
(UCN1, 6 fmoles/100 nl per side, n = 8) or vehicle (n = 8) into the basolateral amygdaloid 
complex (BL) for 5 consecutive days. Anxiety-like behavior was assessed, 24 hr prior to and 48 hr 
following priming, in the social interaction (SI) test. A third group (n = 7) served as undisturbed 
home cage controls. All rats were killed 3 days after the last intra-BL injection to analyze tph2 and 
slc6a4 (gene encoding the serotonin transporter, SERT) mRNA expression in the dorsal raphe 
nucleus (DR), the main source of serotonergic projections to anxiety-related brain regions, using 
in situ hybridization histochemistry.
Results—UCN1 priming increased anxiety-related behavior in the SI test compared to vehicle-
injected controls and elevated tph2, but not slc6a4, mRNA expression in DR subregions, including 
the ventrolateral DR/ventrolateral periaqueductal gray (DRVL/VLPAG), a subregion previously 
implicated in control of panic-related physiologic responses. Tph2 mRNA expression in the 
DRVL/VLPAG was correlated with increased anxiety-related behavior.
Conclusion—Our data support the hypothesis that chronic anxiety states are associated with 
dysregulated tph2 expression.
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Introduction
Anxiety disorders, including social anxiety disorder[1] and panic disorder,[2] are common 
emotional disorders, significantly impair overall quality of life, and affect about 19% of the 
male, and 30% of the female population at some point during life.[3–5] The neural 
mechanisms underlying the manifestation of anxiety disorders are complex. However, two 
interconnected neural systems commonly dysregulated in patients with anxiety disorders are 
the extended amygdala[6, 7] and midbrain serotonergic systems.[8, 9]
Stressful life events are likely a major determinant of vulnerability to affective and anxiety 
disorders.[10–12] Corticotropin-releasing factor (CRF) and CRF-related neuropeptides acting 
at CRF type 1 (CRF1) receptors are thought to play an important role in mediating the 
effects of perceived stress on anxiety-related systems.[13–15] Systemic injections of CRF1 
receptor antagonists are anxiolytic following acute intra-basolateral amygdaloid complex 
(BL) injections of the CRF1/CRF2 receptor agonist[16] urocortin 1 (UCN1) and following 
repeated restraint, suggesting that CRF1 receptors mediate UCN1- and stress-induced 
increases in anxiety-related behavior. [17] When injected into the BL, a key region 
controlling anxiety states,[18,19] UCN1 increases anxiety-related behavior in rats.[20] Under 
chronic stress conditions, CRF receptor-mediated plasticity within the BL contributes to the 
development of chronic anxiety states. [21–24] Repeated activation (priming) of CRF 
receptors within the BL with low-dose UCN1 results in a robust anxiety-like state that 
persists for more than 30 days in rats,[25] as confirmed by reduced social interaction (SI) 
time in the SI test and panic-like physiologic responses, including tachycardia and increased 
respiratory rate, after intravenous administration of sodium lactate,[20,25] an agent used as a 
research probe for panic disorder in human studies.[26–28] In contrast, a single injection of 
the same “sub-threshold” UCN1 dose is insufficient to alter the animals' emotional state,[25] 
indicating the need for BL-neuronal plasticity before a behavioral phenotype is evident.
Family and twin studies have consistently found that genetic factors explain approximately 
48% of the variance in panic disorder,[29] and serotonergic genes are important candidate 
genes for vulnerability to panic disorder.[30] Tryptophan hydroxylase 2 (TPH2) is the rate-
limiting enzyme for brain serotonin (5-HT) synthesis.[31] TPH2 allelic variants appear to be 
genetic predictors of panic disorder itself,[32,33] susceptibility to panic attacks,[34] and 
comorbidity between panic disorder and mood disorders[35] (but see [36,37]). These studies 
are consistent with the hypothesis that allelic variation in TPH2 is associated with increased 
vulnerability to panic disorder.
Selective serotonin reuptake inhibitors (SSRIs) are common, effective treatments for panic 
disorder[38] that target the serotonin transporter (SERT). A number of studies have found no 
association between a functional promoter polymorphism (serotonin transporter-linked 
polymorphic region (5-HTTLPR)) of SLC6A4 (the gene encoding SERT) and panic 
disorder.[39–44] However, recent studies suggest that allelic variation in the SLC6A4 3′ 
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untranslated region may be associated with panic disorder[45, 46] whereas, allelic variation in 
the 5-HTTLPR may be associated with susceptibility to panic attacks in healthy 
volunteers.[47]
Given the functional interactions between the BL and the serotonergic dorsal raphe nucleus 
(DR),[48] evidence for elevated brain serotonin turnover in panic disorder patients[49] and for 
dysfunctional serotonergic systems in a rat model of panic disorder,[50] we here test the 
hypothesis that tph2 and slc6a4 expression are dysregulated in a rat model of chronic 
anxiety with vulnerability to panic-like responses to sodium lactate.[20, 25] To test this 
hypothesis, we conducted sham- or UCN1 priming in the amygdala to generate a chronic 
anxiety state, and measured tph2 and slc6a4 mRNA expression within the DR using in situ 
hybridization histochemistry (ISHH).
Materials and Methods
Animals
Adult male Wistar rats (250–300 g in weight) from Harlan Laboratories (Indianapolis, IN) 
were habituated to the new facility for one week, and housed singly under a 12:12 hr light 
cycle (lights on at 07:00 h) at 22°C with ad libitum access to food and water. Sixteen rats 
were used for intra-BL priming, 16 age-matched conspecifics were used as partner rats in 
the SI test, and seven rats were kept undisturbed as home cage controls. All animal 
procedures were conducted at Indiana University Purdue University at Indianapolis School 
of Medicine (Indianapolis, IN) following IACUC committee approval, and were consistent 
with the Guide for the Care and Use of Laboratory Animals.[51] All efforts were made to 
minimize animal numbers and suffering.
Experimental Design
We utilized an established rat model of chronic anxiety, characterized by increased anxiety 
in the SI test and panic-like physiologic responses following intravenous infusions of 
sodium lactate.[20, 25] The experimental timeline is illustrated in Figure 1. Under deep 
isoflurane anesthesia (MGX Research Machine; Vetamic, Rossville, IN), 16 rats were 
implanted with one stainless steel guide cannula per brain hemisphere (26 ga, Cat. No. 
C315GS-4, Plastics One, Roanoke, VA) above the BL at the following coordinates,[20] 
anterior/posterior: −2.1 mm bregma; lateral from midline (bilateral): ±5.0 mm bregma; 
depth from skull surface: −8.5 mm bregma (Fig. 2),[52] incisor bar at −3.3 mm. After 
surgery, guide cannulae were sealed with dummy cannulae (Plastics One), and rats were 
allowed to recover. Six days later, experimental rats were habituated to the SI arena, and 
tested in the SI test on the following day (Day 0) to measure their baseline anxiety-related 
behavior.[53] Starting one day afterwards, rats received daily, bilateral intra-BL injections of 
vehicle (1% bovine serum albumin, Cat. No. A2153, Sigma-Aldrich, St. Louis, MO, in 
sterile 0.9% saline, n = 8) or the CRF receptor agonist UCN1 (Cat. No. U6631, Sigma-
Aldrich; 6 fmoles UCN1/100 nl vehicle per side, n = 8) into the BL at 09:00 h for 5 
consecutive days.[20] This intra-BL priming paradigm produces long-lasting anxiety-like 
behavior in the SI test and panic-like physiologic responses following lactate challenge, 
whereas a single bilateral injection of the same “sub-threshold” dose of UCN1 is not 
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sufficient to exert anxiogenic actions.[20, 25] This increased anxiety-like state with 
vulnerability to panic-like responses is thought to be dependent on N-methyl-D-aspartic acid 
(NMDA) receptor-dependent neuronal plasticity in the BL.[25] Two days after the last 
injection, the rats were tested in the SI test again to confirm the development of a chronic 
anxiety-like state. We did not challenge rats with sodium lactate in this study as our previous 
studies have shown that sodium lactate,[50] but not exposure to the SI test,[48] profoundly 
activates DR serotonergic neurons, and therefore may, by itself, influence serotonergic gene 
expression. Home cage control rats remained undisturbed during the duration of the 
experiment (n = 7). One day after the postpriming SI test, all rats were killed between 09:00 
and 10:00 h via rapid decapitation. Their brains were collected, shipped overnight on dry ice 
to the University of Colorado Boulder (Boulder, CO), and stored there at −80°C until 
analysis of tph2 and slc6a4 expression. We intentionally killed all rats 24 hr after the 
postpriming SI test, and not earlier, because certain behavioral tests using socially 
interactive paradigms themselves, such as social defeat, have been shown to increase rat 
tph2 mRNA expression within 4 hr post-exposure.[54]
SI Test
The SI test was conducted as described previously.[18, 19, 55, 56] Each experimental rat was 
exposed to an unfamiliar, age- and weight-matched, male partner rat for 5 min in a 91.5 cm 
× 91.5 cm solid wooden box with 30.5-cm high walls and an open top, under low-light 
conditions between 09:00 and 13:00 h. A video camera above the arena recorded the 
behavior for later analysis with “The Observer” (version 5.0, Noldus Information 
Technologies, Wageningen, The Netherlands). SI time was defined as any behavior initiated 
or fully participatory by the experimental rat: face-on contact, sniffing, following, grooming, 
crawling over or under the partner. No experimental rat was exposed to the same partner rat 
more than once. Decreased SI time is indicative of an anxiogenic treatment effect.[53]
Brain Tissue Sectioning and Verification of Cannulae Placements
Forebrains were cryosectioned coronally at 30 μm between approximately −1.40 and −3.60 
mm bregma,[51] thaw-mounted onto Vista-Vision HistoBond microscope slides (VWR 
Scientific, West Chester, PA), stained with cresyl violet,[52] and cover-slipped with Entellan 
mounting medium (Cat. No. 14802, EMS, Hatfield, PA). Cannulae placements (Fig. 2) were 
identified with reference to a stereotaxic rat brain atlas.[52] Only rats with both injection sites 
within the BL region or just ventral of the BL (in which case UCN1 is expected to reach the 
BL along the cannula tract) were used for analysis of behavior and gene expression (Fig. 3). 
No outliers were identified. Hindbrains were cryosectioned at 12 μm between approximately 
−7.58 and −8.67 mm bregma, and sections were thaw-mounted onto VistaVision HistoBond 
microscope slides (VWR Scientific).
tph2 and slc6a4 in situ Hybridization Histochemistry (ISHH)
A 583-base pair fragment of tph2 cDNA was transcribed and radiolabeled with [35-S]-
uridine-5′-triphosphate (UTP, Cat. No. 5610301, MP Biomedicals, Santa Ana, CA) using T7 
RNA-polymerase (Promega, Madison, WI) to create a cRNA probe complementary to bases 
761–1343 of rat tph2 mRNA. The probe was cleaned (RNeasy kit, Cat. No. 74104, Qiagen, 
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Valencia, CA), and used in an ISHH assay as described previously. [57] To detect slc6a4 
mRNA, a synthetic 50-base antisense oligonucleotide probe (5′-ACT GCA GAG TAC CCA 
TTG GAT ATT TGG CTA GGC TCT GCC CTG TCC GCT GT-3′, Integrated DNA 
Technologies, Coralville, IA) complementary to bases 207–256 of rat slc6a4 mRNA was 
used. The probe was labeled at the 3′ end with [35-S]-deoxyadenosine-5′-triphosphate 
(dATP, Cat. No. 5620001, MP Biomedicals, Santa Ana, CA) using terminal 
deoxynucleotidyl transferase (TdT, 20 U/μl, Cat. No. EP0161, Fermentas, Glen Burnie, MD) 
for 1 hr at 37° C in a water bath, cleaned using a QIAquick nucleotide removal kit (Cat. No. 
28304, Qiagen, Valencia, CA), and used in an ISHH assay as described previously. [58] Air-
dried slides were apposed to a BioMax MR autoradiography film (Cat. No. 871 5187, 
Carestream Health, Rochester, NY) for 7 (tph2) or 11 (slc6a4) days, respectively.
Semiquantitative Analysis of Gene Expression
Digital autoradiography images were analyzed with ImageJ (NIH, Bethesda, MD) while 
blinded to the treatment groups to measure gray value × area (equivalent to tph2 or slc6a4 
mRNA expression) using matrices in the shape of each subdivision of the brainstem DR. 
Area (mm2) was defined as the area (within each matrix) that fell above a gray value 
threshold that was kept consistent throughout each gene's analysis. Based on Gardner et 
al.[54] and Abrams et al.,[59] a total of 14 rostro-caudal sections, designated levels +7 to −6 
(Fig. 4), containing seven major subdivisions of the DR were analyzed (rostral aspect of the 
dorsal raphe nucleus, dorsal part, rDRD, −7.580 to −7.916 mm bregma; rostral aspect of the 
dorsal raphe nucleus, ventral part, rDRV, −7.580 to −7.916 mm bregma; caudal aspect of the 
dorsal raphe nucleus, dorsal part, cDRD, −8.000 to −8.336 mm bregma; caudal aspect of the 
dorsal raphe nucleus, ventral part, cDRV, −8.000 to −8.504 mm bregma; dorsal raphe 
nucleus, ventrolateral part/ventrolateral periaqueductal gray region, DRVL/VLPAG, −7.832 
to −8.504 mm bregma; dorsal raphe nucleus, caudal part, DRC, −8.420 to −8.672 mm 
bregma; dorsal raphe nucleus, interfascicular part, DRI, −8.420 to −8.672 mm bregma[52]). 
An average value was computed for the DRVL/VLPAG using values from both the left and 
right hemisphere. The background of each image, measured in the surrounding midbrain 
tegmentum, was subtracted from each value. Throughout the 14 rostrocaudal levels, values 
for each of the seven DR subdivisions were averaged, and average tph2 and slc6a4 
expression levels in the entire DR were also calculated for each rat.
Statistical Analysis
Data were analyzed using PASW (version 19.0, SPSS Inc., Chicago, IL) after elimination of 
statistical outliers.[60] SI time was analyzed using a repeated-measures analysis of variance 
(ANOVA) with treatment (vehicle or UCN1) as the between-subjects factor, and time 
(baseline versus postpriming SI test) as the within-subjects factor, and Fisher's protected 
least significant difference (LSD) tests where appropriate. To determine if vehicle priming 
altered either tph2 or slc6a4 mRNA expression, relative to home cage controls, and if UCN1 
priming altered tph2 or slc6a4 mRNA expression, relative to vehicle-primed rats, we 
conducted two separate repeated-measures ANOVAs, using treatment as the between-
subjects factor and DR subdivision as the within-subjects factor. Where appropriate, Fisher's 
protected LSD tests were applied for each of the seven subdivisions of the DR to reveal 
subdivision-specific treatment effects on gene expression. To compare treatment effects on 
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the average tph2 and slc6a4 mRNA expression in the entire DR, two separate Student's t-
tests were used to compare vehicle-primed rats with home cage controls, and UCN1-primed 
rats with vehicle-primed controls. Significance was accepted at P < .05. Values are shown as 
the mean + the standard error of the mean (SEM).
Results
Behavior in the SI Test
There was no difference in SI time between vehicle and UCN1 groups on Day 0, prior to 
priming, but 48 hr after the final intra-BL priming injection, the UCN1-treated rats displayed 
increased anxiety-like behavior in the SI test, relative to vehicle-treated controls (Fig. 5; 
treatment, F(1, 14) = 3.73, P = 0.07; time, F(1, 14) = 3.65, P = 0.08; time × treatment, F(1,14) = 
12.11, P < 0.01). Also, UCN1-primed rats had significantly less SI time on Day 7 compared 
to the initial test on Day 0 (t = 4.02, P < 0.01), whereas vehicle-primed control rats 
displayed no difference in SI time compared to Day 0.
tph2 mRNA Expression
There were no differences between tph2 expression in vehicle-primed rats and home cage 
control rats (treatment, F(1, 13) = 1.28, P = 0.28; subdivisions, F(6, 8) = 21.48, P < .001; 
subdivisions × treatment, F(6, 8) = 0.36, P = 0.90). UCN1 priming had a significant treatment 
effect on tph2 mRNA expression compared to vehicle-treated rats (treatment, F(1, 14) = 
41.77, P < 0.05; subdivisions, F(6, 9) = 32.02, P < .001; subdivisions × treatment, F(6, 9) = 
2.42, P < 0.05, Fig. 6). Fisher's protected LSD post hoc analyses of each of the seven DR 
subdivisions revealed significantly elevated tph2 mRNA expression within the caudal DRV 
(cDRV, P < 0.05, Fig. 6D) and within the DRVL/VLPAG of UCN1-treated rats compared to 
the vehicle group (P < 0.01, Fig. 6E). No other subdivision showed significant differences in 
priming-induced tph2 expression relative to the vehicle-primed rats. tph2 mRNA expression 
in the entire DR (average of all subregions) did not differ significantly between treatment 
groups (F(2, 20) = 2.98, P= .074; data not shown).
slc6a4 mRNA Expression
No differences in slc6a4 mRNA expression were detected between the vehicle-primed group 
and home cage controls (treatment, F(1, 13) = 0.01, P = 0.94; subdivisions, F(6, 8) = 26.61, P 
< 0.001; subdivisions × treatment, F(6, 8) = 0.34, P = 0.91; Fig. 7). Compared to vehicle-
primed rats, UCN1 priming did not alter the expression of slc6a4 mRNA in subdivisions of 
the DR (treatment, F(1, 14) = 0.05, P = 0.82; subdivisions, F(6, 9) = 37.98, P < 0.001; 
subdivisions × treatment, F(6, 9) = 2.42, P = 0.90; Fig. 7). Slc6a4 mRNA expression in the 
entire DR (average of all subregions) did not differ between treatment groups (F(2, 20) = 
0.02, P = 0.98; data not shown).
Correlation of Behavior and Gene Expression
To address the question of whether the UCN1-induced change in tph2 mRNA expression, 
which presumably already existed during the time of the second behavioral SI test one day 
prior to the collection of the brains, was linked to the observed chronic anxiety state, 
correlation analyses of tph2 mRNA expression in the DRVL/VLPAG or cDRV and SI 
Donner et al. Page 6
Depress Anxiety. Author manuscript; available in PMC 2015 April 29.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
behavior in the SI test of Day 7 were performed for both the vehicle- and the UCN1-primed 
rats (Fig. 8). Anxiety-like behavior during the second SI test was strongly correlated with 
tph2 mRNA expression in the DRVL/VLPAG region (r = 0.73, r2 = 0.53, P < 0.01) but not 
the cDRV region (r = 0.46, r2 = 0.21, P = 0.07). Anxiety-like behavior during the second SI 
test was not correlated with slc6a4 mRNA expression in either the DRVL/VLPAG or 
cDRV.
Discussion
Intra-BL priming with UCN1, a previously characterized rat model of chronic anxiety with 
vulnerability to panic-like physiological responses to sodium lactate challenge (increases in 
blood pressure, heart rate, and respiratory rate),[20, 25] produced a robust anxiety-like state as 
measured in the SI test. In the same rats, tph2 expression was significantly elevated 24 h 
following the SI test in both the cDRV and in the DRVL/VLPAG region. However, only 
tph2 expression in the DRVL/VLPAG showed a strong, positive correlation with increased 
anxiety-like behavior in the post-priming SI test. No other DR subdivision revealed altered 
tph2 expression.
Our finding that the priming-induced anxiety-like state is associated with increased tph2 
mRNA expression in the DRVL/VLPAG is consistent with other models of chronic anxiety 
states that also demonstrated site-specific increases in tph2 mRNA expression in the DRVL/
VLPAG. For example, adverse early-life experiences, such as maternal separation of 
neonatal rats, lead to a chronic anxiety-like state,[61] enhanced vulnerability to social defeat 
induced increases in tph2 mRNA expression specifically within the DRVL/VLPAG region 
during adulthood.[54] Likewise, neonatal administration of Salmonella endotoxin (containing 
gram-negative lipopolysaccharide, LPS) to rat pups, which results in an increased anxiety 
state that lasts into adulthood,[62, 63] also elevates tph2 mRNA expression in the DRVL/
VLPAG, but not in other DR subdivision.[64] The similarities among these three individual 
rat models indicate that site-specific increases in tph2 mRNA expression in the DRVL/
VLPAG region may be a common feature of the development or maintenance of stress-
induced chronic anxiety states.
Although we were not able test both SI behavior and panic-like physiological responses in 
the present study, panic-like physiological responses have been detected when rats of the 
same intra-BL UCN1-priming paradigm were infused intravenously with sodium 
lactate[20,25], an agent that is also used to probe for panic disorder in human 
studies.[27, 28, 65, 66] This vulnerability to panic-like responses following amygdala priming 
may be related to our finding that increased anxiety-like behavior was strongly correlated 
with elevated tph2 expression in the DRVL/VLPAG, because several other lines of evidence 
suggest that DRVL/VLPAG serotonergic neurons play a role in control of panic-like 
responses. For example, an acute challenge with panicogenic stimuli such as sodium lactate 
or hypercapnia, or exposure to adverse stimuli such as forced swimming in cold 
water,[67, 68] strongly activates serotonergic neurons in the DRVL/VLPAG region, as 
indicated by increases in c-Fos expression.[50, 69–71] In studies using a different rat model of 
panic disorder,[26, 65, 66] we have shown that sodium lactate increases c-Fos expression in 
DRVL/VLPAG serotonergic neurons of control rats, but not in rats made panic-prone by 
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disinhibition of the medial hypothalamus.[50, 72] These data suggest that the DRVL/VLPAG 
serotonergic neurons may in fact inhibit panic-like responses. The consequences of priming-
induced increases in tph2 mRNA expression in the DRVL/VLPAG for serotonergic 
neurotransmission are uncertain. Increased tph2 expression in the DRVL/VLPAG may result 
in increased TPH2 protein, increased 5-HT synthesis, and increased 5-HT release in the 
DRVL/VLPAG and targets of DRVL/VLPAG serotonergic neurons. Alternatively, a 
selective increase in serotonergic neurotransmission in the DRVL/VLPAG itself could 
preferentially activate autoinhibitory 5-HT1A receptors, resulting in overall decreased 
serotonergic output from the DRVL/VLPAG to distal target sites. Finally, increased tph2 
mRNA expression could be a compensatory response to decreased serotonergic neural 
activity.
The DRVL/VLPAG contains large, multipolar 5-HT neurons[73] that form part of a 
sympatho-motor command center, controlling both sympathetic outflow via neuronal 
signaling to the adrenal medulla and motor activity via innervation of hind limb muscles.[74] 
Consistent with these anatomic findings, the DRVL/VLPAG is thought to promote passive 
stress coping.[75, 76] Stimulation of the VLPAG region results in passive emotional coping, 
including behavioral quiescence, hyporeactivity to environmental stimuli, hypotension, and 
bradycardia.[75, 76] Therefore, dysfunction of this region could result in dysfunctional 
emotional coping strategies. One target region of the DRVL/VLPAG is the dorsal 
periaqueductal gray (DPAG), an area known to facilitate a panic/escape-like fight-or-flight 
response if disinhibited.[77] Activation of 5-HT1A receptors in the DPAG inhibits panic/
escape-like fight-or-flight responses, and therefore dysregulation of serotonergic signaling in 
this region may lead to increased vulnerability to panic-like responses. The DRVL/VLPAG 
serotonergic neurons also project to the rostral ventrolateral medulla (RVLM[78]); 
stimulation of the DRVL/VLPAG region induces hypotension and sympathoinhibition, 
which can be prevented by activation of 5-HT1A receptors in the RVLM.[79, 80] The DRVL 
also projects to the perifornical region (PeF) of the lateral hypothalamus,[81, 82] a region that 
contains arousal-promoting orexin/hypocretin neurons implicated in anxiety disorders.[83] 
Orexin/hypocretin neurons appear to be tonically inhibited by serotonergic input from the 
DR under normal conditions.[82, 84] Thus, serotonergic neurotransmission arising from the 
DRVL/VLPAG acting in the DPAG, RVLM, and the PeF of the lateral hypothalamus acts to 
inhibit panic-like behavioral and autonomic responses; dysregulation of this serotonergic 
system would be predicted to cause disinhibition of those target areas, leading to panic 
and/or anxiety-like responses, including tachycardia, hypertension, and a state of 
hypervigilance or hyperarousal (see Fig. 9 for a hypothetical mechanistic model).
Amygdala priming with UCN1 also increased tph2 mRNA expression in the cDRV, and the 
correlation between tph2 mRNA expression in the cDRV and anxiety-like behavior in the SI 
test approached statistical significance (P= 0.074). The cDRV contains large numbers of 
neurons projecting to anxiety-related forebrain structures, such as the BL.[85] If the 
hypothesis that increased tph2 mRNA expression ultimately leads to disinhibition of target 
areas holds true, this could mean that increased tph2 expression in the cDRV creates a 
positive feedback loop to the BL, increasing rather than inhibiting the effects of intra-BL 
priming. The DRV is also the main source of efferent projections to the sensorimotor 
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cortex,[86] and DR serotonergic neurons recently have been shown to encode specific 
sensorimotor events.[87] Thus, increases in tph2 in the cDRV may influence encoding of 
specific sensorimotor events. This hypothesis is consistent with findings that panic disorder 
patients have altered processing of sensory information.[88]
The mechanisms underlying selective increases in tph2 mRNA expression in the DRVL/
VLPAG and cDRV region are not clear, but may involve activation of specific afferents. 
The BL does not give rise to direct projections to the DR. Most likely, UCN1 priming of the 
BL causes altered signaling to the central amygdaloid complex (CE), bed nucleus of the stria 
terminalis (BST), and/or the medial prefrontal cortex (mPFC), which are all known to 
innervate the DR, with strong input to the caudal DR and to the DRVL/VLPAG region,[89] 
and may thus alter tph2 expression in the DRVL/VLPAG.
Our observation that expression of slc6a4 mRNA was not altered by intra-BL priming with 
UCN1 is consistent with several studies that failed to find associations between allelic 
variation in SLC6A4 and panic disorder.[39–44] Although SERT binding potential is higher in 
a number of brain regions in male panic disorder patients,[90] unfortunately, no studies have 
evaluated TPH2 or SLC6A4 mRNA expression in postmortem tissues from panic disorder 
patients. Our results are, however, inconsistent with a previous study investigating the 
effects of neonatal maternal separation on vulnerability to social stressors later in life. In this 
study, slc6a4 mRNA was increased, again, specifically in the DRVL/VLPAG region of rats 
that had been exposed to a combination of maternal separation as newborns and acute social 
defeat as adults.[58] This may indicate that slc6a4 expression is more vulnerable to later-life 
social stressors if a vulnerability was created earlier in life, for example during a critical 
developmental window, but that slc6a4 expression is fairly resilient toward repeated 
stressors that have their first occurrence during adulthood.
Conclusion
Our study reveals a potential neuroanatomical pathway by which overstimulation of CRF 
receptors in the BL, for example during chronic stress exposure,[21] could lead to 
dysregulation of serotonergic control of anxiety-related brain circuits. This neuronal 
pathway may contribute to the development of a chronic anxiety state, including 
vulnerability to panic. Our finding that a chronic anxiety state is associated with selective 
dysregulation of the DRVL/VLPAG subset of serotonergic neurons, a panic-related subset 
of serotonergic neurons that is highly sensitive to hypercapnia[70] and sodium lactate,[50] is 
consistent with Klein's suffocation false alarm theory of panic disorder.[91, 92] Finally, as 
suggested by Davies et al.,[93] dysregulation of DRVL/VLPAG serotonergic neurons may 
account for the association between hypertension and panic disorder. Further 
characterization of the DRVL/VLPAG group of serotonergic neurons may lead to novel 
therapeutic strategies for the treatment of anxiety disorders, including panic disorder.
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Figure 1. 
Diagrammatic illustration of the experimental timeline. Adult, male rats underwent 
stereotaxic surgery to implant bilateral guide cannulae into the basolateral amygdaloid 
complex (BL) 6 days before being habituated to the social interaction (SI) arena, and 7 days 
before being tested for baseline anxiety-like behavior in the SI test. On Days 1–5, half of the 
rats received daily bilateral injections of vehicle (1% bovine serum albumin (BSA) in sterile 
0.9% saline, n = 8) into the BL, whereas the other half was primed with a daily bilateral dose 
of urocortin 1 (UCN1, 6 fmoles/100 nl vehicle per side, n = 8). On Day 7, 2 days after the 
last injection, both treatment groups were tested a second time in the SI paradigm. A third 
group of rats (n = 7) did not undergo stereotaxic surgery, behavioral testing, or any other 
treatment, and served as an undisturbed control group. On Day 8, all rats, including those 
from the undisturbed control group, were killed by rapid decapitation and their brains were 
collected for analysis of tph2 and slc6a4 expression using in situ hybridization 
histochemistry (ISHH).
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Figure 2. 
Representative photomicrographs of cannula placements within the basolateral amygdaloid 
complex (BL). Shown is the placement of the injection cannula, and the injection site itself 
in both the left (A) and right (B) hemisphere of a cresyl violet stained coronal brain section 
at −3.30 mm bregma from a urocortin 1 (UCN1)-primed rat. BLA, basolateral amygdaloid 
nucleus, anterior part; BLP, basolateral amygdaloid nucleus, posterior part; BLV, basolateral 
amygdaloid nucleus, ventral part; BMP, basomedial amygdaloid nucleus, posterior part; 
DEn, dorsal endopiriform nucleus; ec, external capsule; LaVL, lateral amygdaloid nucleus, 
ventrolateral part; LaVM, lateral amygdaloid nucleus, ventromedial part; opt, optic tract. 
Scale bar: 1 mm.
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Figure 3. 
Verification and mapping of cannula placements. Bilateral stereotaxic placements of guide 
and injection cannulae within the basolateral amygdaloid complex (BL) were verified via 
histochemistry and comparison with the rat brain atlas by Paxinos and Watson.[51] Depicted 
are all injection sites (black dots) in rat brain sections from rostral (−2.12 mm bregma) to 
caudal (−3.60 mm bregma). The orientation of the brain sections matches the orientation of 
the viewer (left hemisphere on the left, right hemisphere on the right). All injection sites 
were considered successful because of their location within, or their proximity to, the BL 
region. The vertical scale on the right side of each brain section indicates the dorsoventral 
coordinates in millimeters. BLA, basolateral amygdaloid nucleus, anterior part; BLP, 
basolateral amygdaloid nucleus, posterior part; BLV, basolateral amygdaloid nucleus, 
ventral part; BMP, basomedial amygdaloid nucleus, posterior part; LaVL, lateral 
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amygdaloid nucleus, ventrolateral part; LaVM, lateral amygdaloid nucleus, ventromedial 
part; VEn, ventral endopiriform nucleus.
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Figure 4. 
Neuroanatomic atlases of rat tph2 and slc6a4 mRNA expression. Displayed (from top left to 
bottom right of each panel) are 14 representative coronal sections (12 μm) that were used to 
measure tph2 (A) or slc6a4 (B) mRNA expression in all subdivisions of the midbrain dorsal 
raphe nucleus (DR) from rostral (−7.580 mm bregma, designated level +7) to caudal (−8.672 
mm bregma, designated level −6). (A) Photomicrographs are autoradiographic images 
revealing the localization of hybridized 35-S–labeled cRNA probe complementary to tph2 
mRNA. (B) Photomicrographs are autoradiographic images revealing the localization of 
hybridized 35-S–labeled oligonucleotide probe complementary to slc6a4 mRNA. 
Abbreviations are applicable to each following level until indicated differently. cDRD, 
caudal aspect of the dorsal raphe nucleus, dorsal part; cDRV, caudal aspect of the dorsal 
raphe nucleus, ventral part; DRC, dorsal raphe nucleus, caudal part; DRI, dorsal raphe 
nucleus, interfascicular part; DRVL, dorsal raphe nucleus, ventrolateral part; VLPAG, 
ventrolateral periaqueductal gray; rDRD, rostral aspect of the dorsal raphe nucleus, dorsal 
part; rDRV, rostral aspect of the dorsal raphe nucleus, ventral part. Scale bar: 1 mm.
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Figure 5. 
Effects of amygdalar priming on anxiety-related behavior. SI behavior of adult, male rats 
before (Day 0) and after (Day 7) they received daily bilateral injections of vehicle (1% 
bovine serum albumin (BSA) in sterile 0.9% saline, n = 8) or urocortin 1 (UCN1, 6 
fmoles/100 nl vehicle per side, n = 8) into the basolateral amygdaloid complex (BL) for 5 
consecutive days. One week prior to the behavioral testing, all rats had been implanted with 
bilateral guide cannulae targeting the BL. Shown is the mean (+ SEM) time (s, seconds) 
each treatment group spent interacting with a weight- and age-matched conspecific partner 
rat on Days 0 and 7 of the experiment. **P < .01 versus postpriming vehicle. ##P < .01 
versus Day 0.
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Figure 6. 
Effect of amygdalar priming on tph2 mRNA expression. Effect of daily bilateral intra-
basolateral amygdaloid complex (BL) priming with either vehicle (1% bovine serum 
albumin in sterile 0.9% saline, n = 8) or urocortin 1 (UCN1, 6 fmoles/100 nl vehicle per 
side, n = 8) for 5 consecutive days on the expression of tph2 mRNA in the dorsal raphe 
nucleus (DR). All experimental rats were killed one day after the second SI test, meaning 3 
days after the last intra-BL injection, and expression of tph2 mRNA was compared to that of 
an undisturbed control group (control, n = 7). Shown is the mean (+ SEM) tph2 mRNA 
expression in each of the seven subdivisions of the DR (A–G). *P < 0.05 versus vehicle, 
**P < 0.01 versus vehicle; there were no differences between unhandled control rats and 
vehicle-primed rats. caudal DRD, caudal aspect of the dorsal raphe nucleus, dorsal part; 
caudal DRV, caudal aspect of the dorsal raphe nucleus, ventral part; DRC, dorsal raphe 
nucleus, caudal part; DRI, dorsal raphe nucleus, interfascicular part; DRVL/VLPAG, dorsal 
raphe nucleus, ventrolateral part/ventrolateral periaqueductal gray; rostal DRD, rostral 
aspect of the dorsal raphe nucleus, dorsal part; rostal DRV, rostral aspect of the dorsal raphe 
nucleus, ventral part. (H) Representative autoradiograms of tph2 mRNA expression at 
−8.168 mm bregma (designated level 0) in undisturbed controls, and in vehicle- or UCN1-
treated rats. Scale bar: 1 mm.
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Figure 7. 
Effect of amygdalar priming on slc6a4 mRNA expression. Effect of daily bilateral intra-
basolateral amygdaloid complex (BL) priming with either vehicle (1% bovine serum 
albumin in sterile 0.9% saline, n = 8) or urocortin 1 (UCN1, 6 fmoles/100 nl vehicle per 
side, n = 8) for 5 consecutive days on the expression of slc6a4 mRNA in the dorsal raphe 
nucleus (DR). All experimental rats were killed by rapid decapitation one day after the 
second SI test, meaning 3 days after the last intra-BL injection, and expression of slc6a4 
mRNA was compared to that of an undisturbed control group (control, n = 7). Shown is the 
mean (+ SEM) slc6a4 mRNA expression in each of the seven subdivisions of the DR (A–
G). caudal DRD, caudal aspect of the dorsal raphe nucleus, dorsal part; caudal DRV, caudal 
aspect of the dorsal raphe nucleus, ventral part; DRC, dorsal raphe nucleus, caudal part; 
DRI, dorsal raphe nucleus, interfascicular part; DRVL/VLPAG, dorsal raphe nucleus, 
ventrolateral part / ventrolateral periaqueductal gray; rostral DRD, rostral aspect of the 
dorsal raphe nucleus, dorsal part; rostral DRV, rostral aspect of the dorsal raphe nucleus, 
ventral part. (H) Representative autoradiograms of slc6a4 mRNA expression at −8.168 mm 
bregma (designated level 0) in undisturbed controls, and in vehicle- or UCN1-treated rats. 
Scale bar: 1 mm.
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Figure 8. 
Correlation of SI behavior and tph2 mRNA expression. Displayed is the correlation of the 
time (s) that vehicle- or urocortin 1 (UCN1)-primed rats spent socially interacting with a 
weight- and age-matched conspecific partner rat in the SI test on Day 7 of the experiment 
and tph2 mRNA expression in the ventrolateral dorsal raphe nucleus/ventrolateral 
periaqueductal gray (DRVL/VLPAG), measured on Day 8.
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Figure 9. 
Hypothetical model of mechanisms through which amygdalar priming leads to a chronic 
anxiety-like state. Urocortin 1 (UCN1) acts on corticotropin-releasing factor type 1 (CRF1) 
receptors in the basolateral amygdaloid complex (BL) to decrease the inhibitory γ-
aminobutyric acid (GABA)-ergic tone, leading to a hyperexcitability of BL projection 
neurons.[25] The BL gives rise to projections to both the central nucleus of the amygdala 
(CE) and the bed nucleus of the stria terminalis, lateral division, dorsal part (BSTLD), brain 
regions involved in fear- and anxiety-related behavior, respectively,[94,95] that in turn project 
to the lateral wings (dorsal raphe nucleus, ventrolateral part, DRVL/ventrolateral 
periaqueductal gray, VLPAG) of the DR.[96] The finding that amygdala priming enhances 
acquisition of fear-potentiated startle (dependent on the CE) but not light-enhanced startle 
(dependent on the BST[89]) suggests that amygdala priming preferentially increases the 
excitability of the CE, leading to activation of the DRVL/VLPAG. Indeed, panic disorder 
patients show amygdala volume reductions in the corticomedial nuclear group that includes 
the CE.[96] Activation of descending pathways from the CE increases tph2 mRNA 
expression selectively in the DRVL/VLPAG region. Increased tph2 mRNA expression in 
DRVL/VLPAG serotonergic neurons increases tryptophan hydroxylase 2 (TPH2) protein 
and 5-HT release within the DRVL/VLPAG, which leads to activation of autoinhibitory 5-
HT1A receptors, resulting in an overall decreased serotonergic output from the DRVL/
VLPAG to distal target sites, such as the dorsal periaqueductal gray (DPAG), the rostral 
ventrolateral medulla (RVLM), and the perifornical hypothalamus (PeF). In the DPAG, 
decreased 5-HT action on postsynaptic 5-HT1A receptors leads to disinhibition of the 
DPAG[97] and facilitation of panic/escape-like fight-or-flight responses. In the RVLM, 
decreased 5-HT action on postsynaptic 5-HT1A receptors promotes hypertension and 
sympathoexcitation.[98] In the PeF, decreased 5-HT action on postsynaptic 5-HT1A receptors 
leads to hyperactivity of orexin/hypocretin neurons, resulting in hypervigilance, 
hyperarousal, and panic-like responses.[83] Failure to activate DRVL/VLPAG serotonergic 
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neurons is associated with vulnerability to panicogenic agents such as sodium lactate.[50] 
Decreased serotonergic output from the DRVL/VLPAG leads to a chronic anxiety-like state 
with increased vulnerability to panic-like responses.
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